Click here to view online. Add this email to your safelist.

AstraZeneca logo

US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia

14 September 2018

Approval of Lumoxiti, a first-in-class medicine for hairy cell leukaemia marks first new treatment option for patients in over 20 years

75% of patients receiving Lumoxiti achieved an overall response; 30% had a durable complete response

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2018

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.